Time to Refocus on HSV Interventions for HIV Prevention?

Clare Tanton,1 Laith J. Abu-Raddad,2,3 and Helen A. Weiss4

1Research Department of Infection and Population Health, Centre for Sexual Health and HIV Research, University College London, United Kingdom; 2Infectious Disease Epidemiology Group, Weill Cornell Medical College–Qatar, Cornell University, Qatar Foundation, Doha; 3Department of Public Health, Weill Cornell Medical College, Cornell University, New York; and 4MRC Tropical Epidemiology Group, Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, United Kingdom

(See the article by Mugwanya et al, on pages 1912–7.)

In this issue of the Journal, Mugwanya et al. report a crossover randomized controlled trial (RCT) comparing the effect of high-dose valacyclovir (1.5 g twice daily) and standard-dose acyclovir (400 mg twice daily) on plasma human immunodeficiency type 1 (HIV-1) RNA levels. In this proof-of-concept trial, 32 dually HIV-1/Herpes simplex virus type 2 (HSV-2) seropositive individuals not receiving antiretroviral therapy (ART) took each regimen for 12 weeks with a 2-week washout period. Plasma HIV-1 RNA was significantly lower during high-dose valacyclovir treatment (mean, 0.62 log10 copies/mL) compared with levels while not receiving treatment, plasma HIV levels were >1 log10 copies/mL lower when individuals were taking high-dose valacyclovir. High-dose valacyclovir was reported to be well tolerated and safe.

These results provide an impetus to refocus on the potential role of high-dose acyclovir or valacyclovir for preventing HIV transmission and slowing HIV disease progression. In this editorial, we consider whether such a strategy is likely to be effective.

**EPIDEMIOLOGICAL EVIDENCE FOR THE ROLE OF HSV SUPPRESSIVE THERAPY ON HIV TRANSMISSION**

Biological and observational epidemiological evidence for the synergy between HSV-2 and HIV infections led to active research on the potential role of HSV suppression for HIV prevention in the late 1990s/early 2000s [2]. Several proof-of-concept RCTs evaluated the impact of standard-dose HSV suppressive therapy (acyclovir 400 mg or 800 mg twice daily, and valacyclovir 500 mg twice daily) on plasma and genital HIV levels in dually HSV-2/HIV seropositive individuals not yet eligible for ART [3–9]. The trials of valacyclovir and higher dose acyclovir [3, 6, 7, 9] found modest reductions in plasma HIV RNA levels (PVLs) (0.25–0.53 log10 copies/mL) over periods of up to 3 months. Similar effects were seen on genital HIV RNA levels. Smaller or no reductions were seen in trials of standard-dose acyclovir (400 mg twice daily) [4, 5, 8], although adherence was also lower in 2 of these trials, so this differential effect may not be entirely attributable to the different regimen.

The Partners in Prevention HSV/HIV Transmission Study took this research a step further, examining whether standard-dose acyclovir taken by an HIV-positive individual would reduce HIV transmission to their HIV-negative partner [10] and decrease HIV progression [11]. A total of 3408 HIV-discordant couples in 14 sites in Africa were randomized to either acyclovir or placebo and followed up for ≥12 months [10]. A 73% reduction in the occurrence of HSV-2 genital ulcers, and a 0.25 log10 reduction in HIV PVL levels were seen (similar to that seen in the previous studies), but there was no impact of acyclovir on HIV transmission (hazard ratio, 0.92 [95% confidence interval {CI}, 0.61–1.41]). This result, together with results from 2 RCTs showing no effect of standard-dose acyclovir on HIV acquisition [12, 13], essentially halted research on HSV suppression for HIV prevention.

One explanation for the disappointing findings was that this acyclovir dose provided ineffective HSV-2 suppression to reduce HIV transmission. This theory is supported by data presented at the recent International Society for Sexually Transmitted Diseases Research conference, which showed that pharmacokinetic differences result in acyclovir exposure being lower in black African than non-African participants [14]. Higher doses of suppressive therapy may, thus, be needed to reduce HIV transmission in black African populations. Moreover, in vitro studies have shown that acyclovir has a direct effect on HIV-1 reverse transcriptase.
HIV-1 reverse transcriptase is less sensitive to acyclovir than is HSV2; therefore, a higher dose of acyclovir or valacyclovir may increase the direct inhibitory effect on HIV [17]. Results of a study comparing standard-dose acyclovir with valacyclovir 1000 mg daily showed larger reductions in HIV PVL on high-dose HSV suppression, but no difference in HSV suppression [18]. The findings by Mugwanya et al provide additional evidence that high-dose valacyclovir may be more effective than standard dose acyclovir in preventing HIV transmission.

**POPULATION-LEVEL EFFECT OF HSV-2 INFECTION**

On the basis of relative risks from observational studies, Freeman et al estimated that 38%–60% of new HIV infections in women and 8%–49% of new HIV infections in men may be attributable to HSV-2 in sub-Saharan Africa [19]. Mathematical modeling studies have shown that HSV-2 amplified HIV transmission at the population level and its role in the HIV epidemic increased over time [20–22]. HSV-2 has a unique role in the HIV epidemic, compared with other sexually transmitted infections (STIs). Unlike other STIs, which can be sustained only in populations with high rates of partner change, the lifelong nature of HSV-2 infection means that infection can be sustained even in populations with low rates of partner change [22]. The high prevalence of HSV-2, and its role in increasing acquisition and transmission of HIV, have greatly increased the proportion of the population who can sustain HIV [22]. Accordingly, HSV-2 may have played a leading role in fuelling HIV transmission among low-risk populations [22].

**IMPACT OF HSV TREATMENT ON HIV TRANSMISSION**

HIV transmission is closely linked with HIV-1 RNA PVL [23], and provision of ART to reduce PVL is a highly effective method of HIV control for both vertical and sexual transmission [24, 25]. The recent HPTN052 RCT of 1763 HIV-discordant couples from 13 sites in Africa, Asia, and the Americas found that provision of ART at a CD4 count of 350–500 cells/mm³ provided almost complete protection against HIV transmission [24]. The impact of high-dose valacyclovir on HIV PVL is more modest, but substantial reductions in HIV infectiousness can be expected. Using the relationship between HIV PVL and transmission probability per coital act, as measured in the Rakai study [23], a reduction of 1 log₁₀ copies/mL in viral load, similar to that found in Mugwanya et al, implies a reduction of 59% in HIV infectiousness (Figure 1A) [22, 26]. Similarly based on the Partners in Prevention cohort, this decrease may result in a 50%–67% reduction in HIV transmission risk [27].

**IMPACT OF HSV TREATMENT ON THE HIV EPIDEMIC**

The impact of standard-dose HSV suppressive therapy at the population level was estimated by Baggaley et al [28], who found that the reduction in plasma HIV-1 levels seen in 2 trials [5, 7], was likely to result in a very moderate impact, as decreases in infectiousness are counterbalanced by increases in the duration of infectiousness. Mathematical modeling should now explore whether the greater reductions in HIV PVL in the study by Mugwanya and colleagues may lead to a greater population impact overall. Extending earlier modeling work [26, 29], we estimate that such a reduction in HIV PVL may have substantial population level benefits (Figure 1B). A reduction of 1 log₁₀ copies/mL in community HIV viral load, as observed by Mugwanya et al, may reduce HIV prevalence and incidence in the long term by as much as 55%. Achieving such large reductions in PVL at a population level poses challenges but should be considered, particularly where ART provision at CD4 count ≥350 cells/mm³ is not viable.

**EFFECT OF HSV-2 INFECTION AND TREATMENT ON HIV DISEASE PROGRESSION**

Despite the lack of impact on HIV transmission, the Partners in Prevention trial reported a modest effect of HSV suppressive therapy on HIV disease progression [11]. The primary endpoint was either CD4 count <200 cells/mL, ART initiation, or non–trauma-related death. Standard-dose acyclovir reduced the risk of HIV disease progression by 16% (95% CI, 2%–29%) and delayed the risk of CD4 counts falling below 350 cells/mm³ by 19% (95% CI, 7%–29%). A systematic review of observational studies found that with a 1 log₁₀ increase in viral load, risk of HIV progression increased 2-fold [30], suggesting that the larger reduction in HIV PVL observed in the study by Mugwanya et al has the potential for a greater impact on disease progression. In HPTN052, early ART was associated with a 41% reduction in HIV-related clinical events [24]. However, with many countries unable to provide early ART, an intervention that slows disease progression and delays time to ART may be of clinical benefit, in addition to reducing HIV transmission risk.

**CONCLUSIONS**

Mugwanya and colleagues demonstrate that high-dose valacyclovir has a substantial effect on HIV plasma levels, surpassed only by ART. HSV suppressive therapy is simpler to implement than ART, with no laboratory monitoring required. Standard-dose suppressive therapy has been used for many years and has a well-established safety profile. Despite years of use, acyclovir resistance is stable, although more frequent in immune-compromised individuals [31]. No resistant strains were found in genital samples from both HIV-negative and HIV-positive participants of recent trials with >12 months follow-up [32]. However, it would be important to monitor...
for resistant strains. Providing high-dose HSV suppressive therapy to individuals not eligible for ART may have added benefits for HIV patients, including increasing timely ART provision by improving retention in HIV services, as has been suggested for cotrimoxazole prophylaxis in South Africa [33].

There are a number of caveats, however, including whether the effect observed over 12 weeks in this highly controlled trial will translate into an effective real-life, affordable intervention to reduce HIV transmission and progression. Given the direct effect of acyclovir on HIV, there would need to be monitoring for emergent HIV-1 resistant strains as have been reported in vitro [16, 34], although samples analyzed from other HSV suppressive therapy trials do not report emergence of resistant strains [35, 36]. Yet, under current World Health Organization guidelines to start ART at a CD4 count of 350 cells/mm³, these results suggest a potential role for high-dose HSV suppressive therapy to reduce HIV transmission in dually HIV-1/HSV-2 seropositive individuals not yet eligible for ART or who want to delay starting ART.
Notes

Financial support. This work was supported by a Wellcome Trust Value in People award to C. T., the Qatar National Research Fund (NPRP 08-068-3-024 to L. J. A.), and MRC grant G0700837 to H. A. W.

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


